TWI693071B - 硫化寡醣在製備治療手術後肝細胞癌病患之藥物的用途 - Google Patents

硫化寡醣在製備治療手術後肝細胞癌病患之藥物的用途 Download PDF

Info

Publication number
TWI693071B
TWI693071B TW107106359A TW107106359A TWI693071B TW I693071 B TWI693071 B TW I693071B TW 107106359 A TW107106359 A TW 107106359A TW 107106359 A TW107106359 A TW 107106359A TW I693071 B TWI693071 B TW I693071B
Authority
TW
Taiwan
Prior art keywords
hepatocellular carcinoma
patients
tumor
invasion
liver
Prior art date
Application number
TW107106359A
Other languages
English (en)
Chinese (zh)
Other versions
TW201840324A (zh
Inventor
張世忠
賴冠郎
Original Assignee
基亞生物科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 基亞生物科技股份有限公司 filed Critical 基亞生物科技股份有限公司
Publication of TW201840324A publication Critical patent/TW201840324A/zh
Application granted granted Critical
Publication of TWI693071B publication Critical patent/TWI693071B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
TW107106359A 2017-03-01 2018-02-26 硫化寡醣在製備治療手術後肝細胞癌病患之藥物的用途 TWI693071B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762465170P 2017-03-01 2017-03-01
US62/465,270 2017-03-01
US201762504552P 2017-05-11 2017-05-11
US62/504,552 2017-05-11
US201762551770P 2017-08-29 2017-08-29
US62/551,770 2017-08-29

Publications (2)

Publication Number Publication Date
TW201840324A TW201840324A (zh) 2018-11-16
TWI693071B true TWI693071B (zh) 2020-05-11

Family

ID=63357147

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107106359A TWI693071B (zh) 2017-03-01 2018-02-26 硫化寡醣在製備治療手術後肝細胞癌病患之藥物的用途

Country Status (6)

Country Link
US (1) US10842804B2 (cg-RX-API-DMAC7.html)
JP (1) JP6948080B2 (cg-RX-API-DMAC7.html)
KR (1) KR102265159B1 (cg-RX-API-DMAC7.html)
CN (1) CN110381953A (cg-RX-API-DMAC7.html)
TW (1) TWI693071B (cg-RX-API-DMAC7.html)
WO (1) WO2018157762A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113160911A (zh) * 2021-02-26 2021-07-23 杭州臻合健康科技有限公司 一种用于术前肝功能耐受性分析的评估系统
CN117476246B (zh) * 2023-12-25 2024-04-19 福建大数据一级开发有限公司 基于多类型复发事件的患者生存分析方法、介质及装置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101156273B1 (ko) * 2004-03-04 2012-06-13 프로젠 파마슈티칼즈 리미티드 황산화 올리고사카라이드 유도체
JP2014516058A (ja) 2011-06-09 2014-07-07 基亜生物科技股▲ふん▼有限公司 肝癌の再発、悪化または転移の抑制に用いる医薬組成物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Liu, Chun-Jen, et al. "Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence." World Journal of Gastroenterology: WJG 20.32 (2014): 11384.
Liu, Chun-Jen, et al. "Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence." World Journal of Gastroenterology: WJG 20.32 (2014): 11384. Liu, Chun-Jen, et al. "Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage." Journal of hepatology 50.5 (2009): 958-968. Wang, Gui-Bo, Xin-Yu Zhou, and Xiao-Qin Wang. "Relationship between serum heparanase and microscopic venous invasion in patients with hepatocellular carcinoma." American journal of clinical pathology 134.2 (2010): 242-248. *
Liu, Chun-Jen, et al. "Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage." Journal of hepatology 50.5 (2009): 958-968.
Wang, Gui-Bo, Xin-Yu Zhou, and Xiao-Qin Wang. "Relationship between serum heparanase and microscopic venous invasion in patients with hepatocellular carcinoma." American journal of clinical pathology 134.2 (2010): 242-248.

Also Published As

Publication number Publication date
US20180250317A1 (en) 2018-09-06
US10842804B2 (en) 2020-11-24
JP2020509035A (ja) 2020-03-26
JP6948080B2 (ja) 2021-10-13
KR102265159B1 (ko) 2021-06-17
CN110381953A (zh) 2019-10-25
WO2018157762A1 (en) 2018-09-07
TW201840324A (zh) 2018-11-16
KR20190120339A (ko) 2019-10-23

Similar Documents

Publication Publication Date Title
Willemze et al. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
AU2007213920B2 (en) Treatment of metastatic breast cancer
IL270888B2 (en) Systems and methods for identifying cancer treatments from normalized Biosman scores
JP2020514311A (ja) がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ
CN107750165A (zh) 借助塞里班土单抗的组合治疗
Zhang et al. A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028
TW201840324A (zh) 硫化寡醣在製備治療手術後肝細胞癌病患之藥物的用途
TW202043273A (zh) 用於晚期實性瘤癌症之治療性rna
EP4698674A1 (en) Methods to treat glioma in subjects with defined tumour microenvironment
Qiu et al. The debatable role of immune checkpoint blockade therapy in lung adenocarcinoma-oriented liver metastatic malignant lesions
Li et al. Immune myocarditis induced by sintilimab therapy: A case report
US20250186584A1 (en) Methods of treating biliary tract cancer using anti-pd-l1 antibody in combination with chemotherapy
Achaiber sing et al. P07. 19. AA COMPREHENSIVE DRUG-DISCOVERY AND CLINICAL TRIAL PLATFORM FOR GLIOBLASTOMA PATIENTS. REDIRECCT: REPURPOSING DRUGS IN RESEARCH AND CANCER CLINICAL TRIALS.
Subudhi A pilot trial to explore the link between immunological changes, efficacy, safety and tolerability of durvalumab (MEDI4736) plus tremelimumab in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (CRPC)
CONFIDENTIAL et al. A Phase 1b Study to Evaluate safety and clinical activity of Pembrolizumab (MK-3475) in combination with Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC)-(KEYNOTE 173)
Schmid et al. Pembrolizumab Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Triple-Negative Breast Cancer: Results from the Phase 1b Open-Label, Multicohort KEYNOTE-173 Study
EA051386B1 (ru) Соторасиб и антитело к egfr для лечения рака, предусматривающего мутацию kras g12c
EA053269B1 (ru) Способы лечения рака желчных протоков с применением антитела к pd-l1 в сочетании с химиотерапией
Sundahl et al. Randomized Phase 1 Trial of Pembrolizumab with Neo-Adjuvant Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma
Coffey et al. Management of early breast cancer in women over 90: A 10 year experience
Vavolizza MEL 64
Lead et al. Pembrolizumab and Stereotactic Radiotherapy Combined in Subjects with Advanced Hepatocellular Carcinoma–A Phase II Study (PEMRAD) Coordinating Center: Princess Margaret Cancer Centre 610 University Avenue Toronto, ON M5G 2M9
YEAR ANNUAL RESEARCH PROGRESS REPORT
code VHIO19001 Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC)
EA041548B1 (ru) Способ лечения локальных поздних стадий солидных опухолей или метастатических солидных опухолей